TY - JOUR
T1 - Probabilistic evaluation guided IMPT planning with realistic setup and range uncertainties improves the trade-off between OAR sparing and target coverage in neuro-oncological patients
AU - de Jong, Jenneke I.
AU - Habraken, Steven J.M.
AU - Rojo-Santiago, Jesús
AU - Lathouwers, Danny
AU - Perkó, Zoltán
AU - Breedveld, Sebastiaan
AU - Hoogeman, Mischa S.
N1 - Publisher Copyright:
© 2025
PY - 2025/12
Y1 - 2025/12
N2 - Objective: Scenario-based evaluation in proton therapy often relies on a small number of error scenarios, leading to limited insight into the DVH values under uncertainty and suboptimal trade-offs. In this study, we investigated if re-optimization based on probabilistic evaluation improves the trade-off between OAR sparing and target coverage in neuro-oncological patients. Materials and methods: 22 neuro-oncological patients were included. 18 met their original target goals (group A), while in 4, target coverage was compromised to spare OARs (group B). The probabilistic goal for the CTV was calibrated to be consistent with PTV-based photon plans, resulting in D99.8%,CTV = 0.95Dpres with a 90 % confidence level. The probabilistic OAR constraints were set to meet the clinical constraints with a 95 % confidence level. For both groups, the clinical plans were re-optimized, keeping the clinical objectives and constraints, but reducing robustness for the CTV objective (group A) to meet the probabilistic goal, or for the dose-limiting OAR objectives (group B) without exceeding the constraints. For the original and re-optimized plans, polynomial chaos expansion was applied to simulate 10,000 fractionated treatments, deriving probability distributions for relevant DVH parameters.Results: For group A, re-optimization resulted in a population median decrease of 8.2 (range: 0.4–20.8) Gy RBE in the total OAR-related clinical goal values. For group B, re-optimization resulted in a population median increase of 2.7 (range: 1.3–6.8) Gy RBE in the D99.8%,CTV. The population median V95%,CTV improved from 97.4 % to 99.1 %. Conclusion: We demonstrated that probabilistic evaluation guided IMPT planning enables either OAR sparing or target coverage enhancement.
AB - Objective: Scenario-based evaluation in proton therapy often relies on a small number of error scenarios, leading to limited insight into the DVH values under uncertainty and suboptimal trade-offs. In this study, we investigated if re-optimization based on probabilistic evaluation improves the trade-off between OAR sparing and target coverage in neuro-oncological patients. Materials and methods: 22 neuro-oncological patients were included. 18 met their original target goals (group A), while in 4, target coverage was compromised to spare OARs (group B). The probabilistic goal for the CTV was calibrated to be consistent with PTV-based photon plans, resulting in D99.8%,CTV = 0.95Dpres with a 90 % confidence level. The probabilistic OAR constraints were set to meet the clinical constraints with a 95 % confidence level. For both groups, the clinical plans were re-optimized, keeping the clinical objectives and constraints, but reducing robustness for the CTV objective (group A) to meet the probabilistic goal, or for the dose-limiting OAR objectives (group B) without exceeding the constraints. For the original and re-optimized plans, polynomial chaos expansion was applied to simulate 10,000 fractionated treatments, deriving probability distributions for relevant DVH parameters.Results: For group A, re-optimization resulted in a population median decrease of 8.2 (range: 0.4–20.8) Gy RBE in the total OAR-related clinical goal values. For group B, re-optimization resulted in a population median increase of 2.7 (range: 1.3–6.8) Gy RBE in the D99.8%,CTV. The population median V95%,CTV improved from 97.4 % to 99.1 %. Conclusion: We demonstrated that probabilistic evaluation guided IMPT planning enables either OAR sparing or target coverage enhancement.
UR - https://www.scopus.com/pages/publications/105017227907
U2 - 10.1016/j.radonc.2025.111171
DO - 10.1016/j.radonc.2025.111171
M3 - Article
C2 - 41022254
AN - SCOPUS:105017227907
SN - 0167-8140
VL - 213
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 111171
ER -